title: The effects of a selective 5-HT2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers.
abstract: 1. ICI 170,809 (2-(2-dimethylamino-2-methylpropylthio)-3-phenylquinoline hydrochloride) is a potent 5-hydroxytryptamine (5-HT) type 2 postsynaptic receptor antagonist. 2. Effects of ICI 170,809 as single oral doses (3, 7, 15 and 30 mg) or placebo were studied on the duration of antagonism for the ex vivo platelet aggregatory response to 5-HT and to the pupillary light constrictor response in eight healthy male volunteers. 3. Pupillary dark adapted responses to a 0.5 s light stimulus were measured using a portable infrared pupillometer, for up to 24 h after dosing. 4. The in vitro platelet 5-HT aggregation response was reduced by ICI 170,809, with depression of the dose-response curve to 5-HT at all concentrations of 5-HT and with no evidence for a parallel shift. 5. The ex vivo platelet 5-HT response demonstrated a dose related significant (P less than 0.02) decrease in aggregation reaching a maximum at 2 h after dosing with the effect persisting for at least 8 h after dosing with the 7 and 15 mg doses. 6. Resting pupil diameter (RPD), and light induced pupillary responses in the dark adapted pupil, showed a significant (P less than 0.01) dose related reduction with significant (P less than 0.05) effects still present with the 15 and 30 mg doses at 8 h after dosing. 7. We conclude that, changes in both ex vivo platelet aggregation to 5-HT and dark adapted pupil size, are significantly correlated (P less than 0.0001) with log plasma concentrations (ng ml-1) of ICI 170,809, enabling the assessment of 5-HT2-receptor antagonism in man.
authors.affiliation: ICI Pharmaceuticals, Macclesfield, Cheshire.
authors.forename: D S
authors.initials: DS
authors.lastname: Millson
authors.forename: C L
authors.initials: CL
authors.lastname: Jessup
authors.forename: A
authors.initials: A
authors.lastname: Swaisland
authors.forename: S
authors.initials: S
authors.lastname: Haworth
authors.forename: A
authors.initials: A
authors.lastname: Rushton
authors.forename: J D
authors.initials: JD
authors.lastname: Harry
mesh_terms: D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D011680:Pupil / Q000187:drug effects*; D011804:Quinolines / Q000493:pharmacokinetics / Q000494:pharmacology*; D012016:Reference Values; D012701:Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D010975:Platelet Aggregation Inhibitors; D011804:Quinolines; D012702:Serotonin Antagonists; D012701:Serotonin; C060632:ICI 170809